EGFR and hepatocellular carcinoma: Accordingly, combined treatment with the EGFR inhibitor gefitinib and lenvatinib exerts strong anti-proliferative effects in EGFR-expressing liver cancer cell lines in vitro, as well as in xenografted cell lines, immunocompetent mouse models, and patient-derived HCC xenografts in vivo [134].